Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

This promotional meeting is organised and funded by Novo Nordisk and Abbott.
Marketing and organisational support has been provided by OmniaMed Communications.
The information presented at this meeting is for UK-based healthcare professionals only.
Adverse event reporting information and links to prescribing information are available below.
Prescribing information will be available at the webinar.
© 2021 Novo Nordisk and Abbott.

Delegates should use headphones and their screens must not be readily visible to the public.

In association with

Small changes can make a big difference to Time in Range:

Exploring the role of technology and modern insulins for improving glycaemic control in diabetes

*Recommended Time in Range for most adults with type 1 diabetes or type 2 diabetes and non-pregnant adults regardless of insulin therapy.
†Readings >13.9 mmol/L are also included
‡Readings <3.0 mmol/L are also included
This visual was adapted from Battelino T et al. (2019) Diabetes Care 42:1593–603

This 1-hour promotional webinar will be broadcast on
Monday 29 November
2021
at 13:00 and 19:00

Next event starting shortly. Already registered?

Taking place online

Small changes can make a big difference to Time in Range:

Exploring the role of technology and modern insulins for improving glycaemic control in diabetes

Time in Range (TIR) is a glycaemic measure of the amount of time that a person with diabetes spends within the target glucose range. It is easily understandable for people with diabetes and healthcare professionals alike, and is rapidly responsive to changes in diet, lifestyle and medication in day-to-day diabetes management. As such it is of great value in routine clinical care1.

Join us for a live webinar on Monday 29 November at 13:00 and 19:00 hosted by Dr Emma Wilmot, Consultant Diabetologist from University Hospitals of Derby and Burton NHS Foundation Trust, Associate Professor, University of Nottingham and Dr Peter Jennings, Senior Lecturer at Birmingham City University – Diabetes MSc Course. This webinar will explore how small changes to everyday diabetes management can impact TIR, and how glucose monitoring technology with the optimal use of modern insulins can help improve glycaemic control.

Reference
1. Wilmot EG et al. Diabet Med 2021;38:e14433

What does this programme offer?

Live Q&A session with Dr Emma Wilmot and Dr Peter Jennings ready to answer your burning questions
On-demand resources – access education at times that work for you
Register for free today and gain access to this event

Join us for our upcoming webinar

The webinar will be broadcast on Monday 29 November
at 13:00 and 19:00

Speakers

Dr Emma Wilmot

MB ChB BSc (hons) PhD FRCP
Consultant Diabetologist, University Hospitals of Derby and Burton NHS Foundation Trust, Associate Professor, University of Nottingham

Dr Emma Wilmot is a Consultant Diabetologist at University Hospitals of Derby and Burton NHS Foundation Trust, Associate Professor, University of Nottingham. In 2018 she was appointed as an Honorary (consultant) Assistant Professor at the University of Nottingham. Her specialist interests include Type 1 diabetes, insulin pump therapy and diabetes technology, young adults with diabetes and antenatal diabetes care.

Dr Wilmot is founder of the Association of British Clinical Diabetologists (ABCD) Diabetes Technology Network UK, an elected ABCD committee member and Dose Adjustment For Normal Eating (DAFNE) structured education executive board member. She is a member of the National Diabetes Audit Insulin Pump Expert Reference Group and has also been involved in the #languagematters movement. She is the principal investigator on several diabetes research trials.

Dr Peter Jennings

Senior Lecturer, Birmingham City University – Diabetes MSc Course

Dr Peter Jennings coaches and educates healthcare professionals to support people to optimally self-manage their type 1 diabetes. He currently works as a Senior Lecturer at Birmingham City University and has worked as a Diabetes Specialist Nurse at University Hospitals of Derby and Burton NHS Foundation Trust. Peter has special interests in education, glucose sensing, insulin pump therapy, closed-loop systems and coaching health care professionals. Peter has been living with Type 1 Diabetes for over 30 years.

GB Prescribing Information for Fiasp® FlexTouch (insulin aspart) can be found here
GB Prescribing Information for Fiasp® Penfill (insulin aspart) can be found here
GB Prescribing Information for Fiasp® Vial (insulin aspart) can be found here
NI Prescribing Information for Fiasp® (insulin aspart) can be found here
GB Prescribing Information for Tresiba® (insulin degludec) can be found here
NI Prescribing Information for Tresiba® (insulin degludec) can be found here

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes.

Job code: UK21DI00341, ADC-43965 V1.0 | Date of preparation: October 2021

You are leaving this site.

You are now leaving https://live.diabetesonthenet.com/small-changes-can-make-a-big-difference-to-time-in-range-exploring-the-role-of-technology-and-innovative-insulins-for-improving-glycaemic-control-in-diabetes-decomm.
Links to external website are provided as a resource to the viewer.
This website is neither owned nor controlled by Novo Nordisk or Abbott. Novo Nordisk and Abbott accept no responsibility for the content or services of the linked site.

This website is for healthcare professionals

This website is for UK and ROI healthcare professionals only. To continue, please confirm that you are a UK or ROI healthcare professional by clicking the ‘Confirm’ button below.

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.